Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monocentric single-arm study of Revestive (teduglutide) in pediatric short bowel syndrome patients on home parenteral nutrition
2017-001405-32Phase 4Completed
- Sponsor
- Institut Imagine
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Institut Imagine. Primary endpoint: Proportion of patients achieving ≥20% reduction in PN/REE at week 24. Started Sep 2017; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2017-001405-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001405-32.